ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine]: I. A potent and selective cholinergic channel modulator with neuroprotective properties

Journal of Pharmacology and Experimental Therapeutics

Volumn 283, Issue 1, 1997, Pages 235-246

  Sullivan, James P ^a   Donnelly Roberts, Diana ^a   Briggs, Clark A ^a   Anderson, David J ^a   Gopalakrishnan, Murali ^a   Xue, Iris C ^a   Piattoni Kaplan, Marietta ^a   Molinari, Eduardo ^a   Campbell, Jeffrey E ^a   Mckenna, David G ^a   Gunn, David E ^a   Lin, Nan Horng ^a   Ryther, Keith B ^a   He, Yun ^a   Holladay, Mark W ^a   Wonnacott, Susan ^b   Willams, Michael ^a   Arneric, Stephen P ^a  

^a ABBOTT LABORATORIES   (United States)

^b UNIVERSITY OF BATH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYL 3 (2 PYRROLIDINYLMETHOXY)PYRIDINE; 3 METHYL 5 (1 METHYL 2 PYRROLIDINYL)ISOXAZOLE; A 94224; CHOLINERGIC RECEPTOR STIMULATING AGENT; NICOTINIC AGENT; UNCLASSIFIED DRUG;

ACETYLCHOLINE RELEASE; ARTICLE; CHOLINERGIC SYSTEM; CONTROLLED STUDY; DOPAMINE RELEASE; HUMAN TISSUE; NEUROPROTECTION; NEUROTOXICITY; NEUROTRANSMITTER RELEASE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR BINDING; SYNAPTOSOME; THALAMUS;

ACETYLCHOLINE; ALKALOIDS; ANIMALS; AZOCINES; CHOLINERGIC AGENTS; DOPAMINE; HUMANS; ION CHANNELS; MALE; MICE; NEUROPROTECTIVE AGENTS; PYRIDINES; PYRROLIDINES; QUINOLIZINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NICOTINIC; RUBIDIUM RADIOISOTOPES; XENOPUS LAEVIS;

EID: 15444351510     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. AKAIKE, A., TAMURA, Y., YOKOTA, T., SHIMOHAMA, S. AND KIMURA, J.: Nicotineinduced protection of cultured cortical neurons against N-methyl-D-aspartate receptor-mediated glutamate cytotoxicity. Brain Res. 644: 181-187 1994.
2. 3H]ABT-418: A novel cholinergic channel ligand. J. Pharmacol. Exp. Ther. 273: 1434-1441, 1995.
3. ARNERIC, S. P., SULLIVAN, J. P., BRIGGS, C. A., DONNELLY-ROBERTS, D., ANDERSON, D. J., RASZKIEWICZ, J. L., HUGHES, M., CADMAN, E. D., ADAMS, P., GARVEY, D. S., WASICAK, J. AND WILLIAMS, M.: (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl) isoxazole (ABT-418): A novel cholinergic channel ligand with cognition enhancing and anxiolytic activity: In vitro activity. J. Pharmacol. Exp. Ther. 270: 310-317, 1994.
4. ARNERIC, S. P., ANDERSON, D. A, BANNON, A. D, BRIONI, J. D., BRIGGS, C. A., BUCCAFUSCO, J., DECKER, M. W., DONNELLY-ROBERTS, D., GOPALAKRISHNAN, M., HOLLADAY, M. W. AND SULLIVAN, J. P.: Preclinical pharmacology of ABT-418: A prototypical cholinergic channel activator for the treatment of Alzheimer's disease. CNS Drug Rev. 1: 1-26, 1995.
5. ARNERIC, S. P., HOLLADAY, M. W. AND SULLIVAN, J. P.: Cholinergic channel modulators as a novel therapeutic strategy for Alzheimer's disease. Exp. Op. Invest. New Drugs 5: 79-100, 1996a.
6. ARNERIC, S. P., BANNON, A. W., BRIGGS, C. A., BRIONI, J. D., BUCCAFUSCO, J. J., DECKER, M. W., DONNELLY-ROBERTS, D. L., GOPALAKRISHNAN, M., HOLLADAY, M. W., KYNCL, J., LIN, N. H., MARSH, K. C., QUI, Y., RADEK, R., SULLIVAN, J. P. AND WILLIAMS, M.: ABT-089: An orally active cholinergic channel modulator with cognition enhancing and neuroprotective activity. In Alzheimer Disease: From Molecular Biology to Therapy, ed. by R. Becker, E. Giacobini and P. Robert, pp. 287-292, Birkhauser Boston Inc., New York, 1996b.
7. BERTRAND, D. L. AND CHANGEUX, J. P.: Nicotinic receptor: An allosteric protein specialized for intracellular communication. Semin. Neurosci. 7: 75-90, 1995.
8. BRIGGS, C. A., MCKENNA, D. G. AND PIATTONI-KAPLAN, M.: Human α7 nicotinic acetylcholine receptor responses to novel ligands. Neuropharmacology 34: 583-590, 1995.
9. BRIGGS, C. A., ANDERSON, D. J., BRIONI, J. D., BUCCAFUSCO, J. J., BUCKLEY, M. J., CAMPBELL, J. E., DECKER, M. W., DONNELLY-ROBERTS, D., ELLIOTT, R. L., HOLLADAY, M. W., HUI, Y. H., JACKSON, W. J., KIM, D. J., MARSH, K. C., O'NEILL, A., PRENDERGAST, M. A., RYTHER, K. B., SULLIVAN, J. P. AND ARNERIC, S. P.: Functional characterization of the novel neuronal nicotinic acetylcholine receptor ligand GTS-21 in vitro and in vivo. Pharmacol. Biochem. Behav. 57: 231-241, 1997.
10. BRIONI, J. D., O'NEILL, A., KIM, D. J. B. AND DECKER, M. W.: Nicotinic receptor agonists exhibit anxiolytic-like effects on the elevated plus-maze. Eur. J. Pharmacol. 238: 1-8, 1993.
11. BRIONI, J. D., MORGAN, S. J., O'NEILL, A. B., SYKORA, T. M., POSTL, S. P., PAN, J. B., SULLIVAN, J. P. AND ARNERIC, S. P.: In vivo profile of novel nicotinic ligands with CNS selectivity. Med. Chem. Res. 487-510, 1996.
12. 50) of an enzymatic reaction. Biochem. Pharmacol. 22: 3099-3108, 1972.
13. 125I]-α-bungarotoxin. J. Neurosci. 5: 1307-1315, 1985.
14. COYLE, J. T., PRICE, D. L. AND DELONG, M. R.: Alzheimer's disease: A disorder of cholinergic innervation. Science 219: 1184-1190, 1983.
15. DECKER, M. W., BRIONI, J. D., SULLIVAN, J. P., BUCKLEY, M. J., RADEK, R. J., RASZKIEWICZ, J. L., KANG, C.-H., KIM, D. J. B., GIARDINA, W., WASICAK, J., WILLIAMS, M. AND ARNERIC, S. P.: (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl) isoxazole (ABT-418): A novel cholinergic ligand with cognition enhancing and anxiolytic activities II: In vivo characterization. J. Pharmacol. Exp. Ther. 270: 317-324, 1994.
16. DECKER, M. W., BANNON, A. W., CURZON, P., GUNTHER, K. L., BRIONI, J. D., HOLLADAY, M. W., LIN, N. H., LI, Y., DAANEN, J. F., BUCCAFUSCO, J. J., PRENDERGAST, M. A., JACKSON, W. J. AND ARNERIC, S. P.: ABT-089 [2-Methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine dihydrochloride]: II. A novel cholinergic channel modulator with effects on cognitive performance in rats and monkeys. J. Pharmacol. Exp. Ther. 283: 247-258, 1997.
17. 125I]-α-bungarotoxin receptor subtypes. Mol. Pharmacol. 47: 164-171, 1995.
18. DENERIS, E. S., CONNOLLY, J. ROGERS, S. W. AND DUVOISIN, R.: Pharmacological and functional diversity of neuronal nicotinic acetylcholine receptors. Trends Pharmacol. Sci. 12: 34-40, 1991.
19. DONNELLY-ROBERTS, D. L., XUE, I., ARNERIC, S. P. AND SULLIVAN, J. P.: In vitro neuroprotective properties of the novel cholinergic channel activator (ChCA), ABT-418. Brain Res. 719: 36-44, 1996.
20. ELGOYHEN, A. B., JOHNSON, D. S., BOULTER J., VETTER, D. AND HEINEMANN, S.: α9: An acetylcholine receptor with novel pharmacological properties expressed in rat cochlear hair cells. Cell 79: 705-715, 1994.
21. ENNA, S. J. AND SNYDER, S. H.: Properties of γ-Aminobutyric acid receptor binding in rat brain synaptic membrane fractions. Mol. Pharmacol. 13: 422-433, 1977.
22. FLORES, C. M., ROGERS, S. W., PABREZA, L. A., WOLFE, B. AND KELLAR, K. J.: A subtype of nicotinic cholinergic receptor is composed of α4 and β2 subunits and is upregulated by chronic nicotine treatment. Mol. Pharmacol. 41: 31-37, 1992.
23. GERZANICH, V., ANAND, R. AND LINDSTROM, J.: Homomers of α8 and α7 subunits of nicotinic receptors exhibit similar channel but contrasting binding site properties. Mol. Pharmacol. 45: 212-220, 1994.
24. GOPALAKRISHNAN, M., BUISSON, B., TUOMA, E., GIORDANO, T., CAMPBELL, J. E., HU, I. C., BERTRAND, D., DONNELLY-ROBERTS, D., ARNERIC, S. P. AND SULLIVAN, J. P.: Pharmacological characterization of the human α7 neuronal nicotinic acetylcholine receptor subtype stably expressed in a mammalian cell line. Eur. J. Pharmacol. 290: 237-246, 1995.
25. GOPALAKRISHNAN. M., MONTEGGIA, L. M., ANDERSON, ARNERIC, S. P. AND SULLIVAN, J. P.: Stable expression, pharmacologic properties and regulation of human nicotinic acetylcholine α4β2 receptor. J. Pharmacol Exp. Ther. 276: 289-297, 1996.
26. HOLLADAY, M. H., LEBOLD, S. A. AND LIN, N.-H.: Structure activity relationships of nicotinic acetylcholine agonists as potential treatments for dementia. Drug Dev. Res. 35: 191-213, 1995.
27. LEVIN, E.: Nicotinic systems and cognitive function. Psychopharmacology 108: 417-421, 1992.
28. LIN, N. H., GUNN, D. E., RYTHER, K. B., GARVEY, D. S., DONNELLY-ROBERTS, D. L., DECKER, M. W., BRIONI, J. D., BUCKLEY, M. J., RODRIGUES, A. D., MARSH, K. G., ANDERSON, D. J., BUCCAFUSCO, J. D., PRENDERGASTT, M. A., SULLIVAN, J. P., WILLIAMS, M., ARNERIC, S. P. AND HOLLADAY, M. W.: Structure-activity studies on ABT-089: An orally bioavailable 3-pyridyl ether nicotinic acetylcholine receptor ligand with cognition enhancing properties. J. Med. Chem. 40: 385-390, 1997.
29. LINVILLE, D. G., WILLIAMS, S., RASZKIEWICZ, J. L. AND ARNERIC S. P.: Nicotinic agonists modulate basal forebrain (BF) control of cortical cerebral blood flow in anesthetized rats. J. Pharmacol. Exp. Ther. 267: 440-461, 1993.
30. 3H] nicotine binding to putative high affinity receptor sites in rat brain. Mol. Pharmacol. 31: 392-400, 1987.
31. LISTERUD, M., BRASSAARD, A. B., DEVAY, P., COLMAN, D. R. AND ROLE, L. W.: Functional contribution of neuronal AChR subunits revealed by antisense oligonucleotides. Science 254: 1518-1521, 1991.
32. LLOYD, G. K., RAO, T. S., SACAAN, A., REID, R. T., CORREA, L. D., WHELAN, A. K., RISBROUGH, V. AND MENZAGHI, F. M.: SIB1765F, a novel nicotinic agonist: profile in models of extrapyramidal motor function. Soc. Neurosci. Abstr. 21: 11.10, 1995.
33. LUKAS, R. J.: Characterization of curaremimetic neurotoxin binding sites on membrane fractions derived from the human medulloblastoma clonal line TE671. J. Neurochem. 46: 1936-1941, 1986.
34. LUKAS, R. J.: Expression of ganglia-type nicotinic acetylcholine receptors and nicotinic ligand binding sites by cells of the IMR-32 human neuroblastoma clonal cell line. J. Pharmacol. Exp. Ther. 265: 294-302, 1993.
35. MARIN, P., MAUS, M., DESAGHER, S., GLOWINSKI, J. AND PREMONT, J.: Nicotine protects cultured striatal neurones against N-methyl-D-aspartate-receptor-mediated neurotoxicity. Neuroreport 5: 1977-1980, 1994.
36. MARKS, M. J., FARNHAM, D. A., GRADY, S. R. AND COLLINS, A. C.: Nicotinic receptor function determined by stimulation of rubidium efflux from mouse brain synaptosomes. J. Pharmacol. Exp. Ther. 264: 542-552, 1993.
37. MARTIN, E. J., PANICKAR, K. S., KING, M. A., DEYRUP, M., HUNTER, B. E., WANG, G. AND MEYER, E. M.: Neuroprotective actions of 2,4-dimethoxybenzylidene anabaseine in differentiated PC12 cells and septal cholinergic neurons. Drug. Dev. Res. 31: 135-141, 1994.
38. MCGEHEE, D. S. AND ROLE, L. W.: Physiological diversity of nicotinic acetylcholine receptors expressed by vertebrate neurons. Annu. Rev. Physiol. 57: 521-546, 1995.
39. MCGEHEE, D. S., HEATH, M. J. S., GELBER, S., DEVAY, P. AND ROLE, L. W.: Nicotine enhancement of fast synaptic transmission in CNS by presynaptic receptors. Science 269: 1692-1696, 1995.
40. MEYER, E. M., DEFIEBRE, C. M., HUNTER, B. E., SIMPKINS, C. E., FRAUWORTH, N. AND DEFIEBRE, N. E. C.: Effect of anabaseine-related analogs on rat brain receptor binding and on avoidance behaviors. Drug Dev. Res. 31: 127-134, 1994.
41. NEWHOUSE, P. A., POTTER, A., CORWIN, J., LANG, J. AND LENNOX, R.: Acute administration of the cholinergic channel activator ABT-418 improves learning in Alzheimer's disease. Psychopharmacology, in press, 1997.
42. PAPKE, R. L. AND HEINEMANN, S. F.: Partial agonist properties of cytisine on neuronal nicotinic receptors containing the beta2 subunit. Mol. Pharmacol. 45: 142-149, 1993.
43. ROLE, L. W. AND BERG, D. K.: Nicotinic receptors in the development and modulation of CNS synapses. Neuron 16: 1077-1085, 1996.
44. SACAAN, A., DUNLOP, J. L. AND LLOYD, G. K.: Pharmacological characterization of neuronal acetylcholine-gated ion channel receptor-mediated hippocampal norepinephrine and striatal dopamine release from rat brain slices. J. pharmacol. Exp. Ther. 274: 224-230, 1995.
45. SARGENT, P. B.: The diversity of neuronal nicotinic acetylcholine receptors. Annu. Rev. Neurosci. 16: 403-443, 1993.
46. SEGUELA, P., WADICHE, J., DINELEY-MILLER, K., DANI, J. A. AND PATRICK, J. W.: Molecular cloning, functional properties and distribution of rat brain α7; A nicotinic cation channel highly permeable to calcium. J. Neurosci. 13: 596-604, 1993.
47. SULLIVAN, J. P. AND BANNON, A.: Epibatidine: Pharmacological properties of a novel nicotinic acetylcholine receptor agonist and analgesic agent. CNS Drug Rev. 2: 21-39, 1996.
48. SULLIVAN, J. P., DECKER, M. W., BRIONI, J. D., ROBERTS-DONNELLY, D., ANDERSON, D. J., BANNON, A., GOPALAKRISHNAN, M., PIATTONI-KAPLAN, M., ADAMS, P., BUCKLEY, M. J., KANG, C. H., WILLIAMS, M. AND ARNERIC, S. P.: Pharmacological properties of (±)-epibatidine: A potent nicotinic acetylcholine receptor ligand. J. Pharmacol. Exp. Ther. 271: 624-631, 1994.
49. WADA, E., WADA, K., BOULTER, J., DENERIS, E., HEINEMANN, S., PATRICK, J. AND SWANSON, L. W.: Distribution of alpha-2, alpha-3, alpha4 and beta-2 neuronal nicotinic receptor subunit mRNAs in the central nervous system: A hybridization histochemical study in the rat. J. Comp. Neurol. 284: 314-338, 1989.
50. WHITING, P., SCHOEPFER, R., LINDSTROM, J. AND PRIESTLY, T.: Structural and pharmacological characterization of the major brain nicotinic acetylcholine receptor subtype stably expressed in mouse fibroblasts. Mol. Pharmacol 40: 463-472, 1991.
51. WILLIAMS, M., SULLIVAN, J. P. AND ARNERIC, S. P.: Neuronal nicotinic acetylcholine receptors. Drug News Perspect. 7: 205-223, 1994.
52. WONG, E. T., HOLSTAD, S. G., MENNERICK, S. J., HONG, S. E., ZORUMSKI C. F. AND ISENBERG, K. E.: Pharmacological and physiological properties of a putative ganglionic nicotinic receptor, α3β4, expressed in transfected eucaryotic cells. Mol. Brain Res. 28: 101-109 1995.
53. WONNACOTT, S., IRONS, J., RAPIER, C., THORNE, B. AND LUNT, G. G.: Presynaptic modulation of transmitter release by nicotinic receptors. In Progress in Brain Research, ed. by A. Nordberg, K. Fuxe, B. Holmstedt and A. Sundwall A, pp. 157-163, Elsevier, Amsterdam, 1990.
54. WONNACOTT, S.: Presynaptic nicotinic receptors. Trends Neurosci. 20: 92-98, 1997.
55. WOODRUFF-PAK, D. S., LI, Y.-T. AND KEM, W. R.: A nicotinic agonist (GST-21), eyeblink classical conditioning, and nicotinic receptor binding in rabbit brain. Brain Res. 645: 309-317, 1994.